For the very first time, the US Food and Drug Administration has approved a drug specifically indicated for the treatment of postpartum depression, which experts say offers new hope to women and physicians. CNN reports that on Tuesday the FDA announced the approval of an intravenous infusion of the drug brexanolone, which will be sold as Zulresso. It has been shown in clinical trials to work within hours to treat the symptoms of postpartum depression, a serious mental illness that impacts 1 in 9 new mothers after childbirth.

https://www.cnn.com/2019/03/19/health/postpartum-depression-drug-fda-bn/...

Advertisement
Up to 50% Off Men''s Shorts at Eastern Mountain Sports. Hurry, While Supplies Last!

More videos

NBA 17 Jul 2019 03:00 CEST

Best of Plays!